The Association between Pretreatment anemia and Overall Survival in Advanced Non-small Cell lung Cancer: A Retrospective Cohort Study Using Propensity Score Matching
Yucong Huang, Cuiyun Su, Huiqin Jiang, Feiwen Liu, Qitao Yu, Shaozhang Zhou · Journal of Cancer · 2021
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2021
Abstract
Background: The purpose of this study was to investigate whether pretreatment anemia was an independent risk factor for survival in patients with advanced non-small cell lung cancer (NSCLC) after adjusting for other covariates.
Methods:We used propensity score matching (PSM) to minimize the influence of confounding factors and used χ2 (categorical variables), Student's t-test (normal distribution), or Mann-Whitney U test (skewed distribution) to analyze the differences among the Hb groups.Cox regression and Kaplan-Meier analyses were used to assess the association between anemia and survival.P values < 0.05 (two-sided) were considered statistically significant.Results: The average age of the 758 selected participants was 58.2±11 years, and 210 patients (27.7%) had anemia.In the multivariate analysis, anemia was associated with a poor prognosis in the unmatched cohort (Hazards ratio (HR)=1.3,95% (confidence interval (CI): 1.1-1.6;p= 0.008), and the matched cohort (HR=1.7,95% CI: 1.3-2.3;p <0.001), emerging as an independent risk and prognostic factor in advanced NSCLC patients.In the Kaplan-Meier curve, the average survival time of anemic and non-anemic patients was 9.3 months (95% CI: 7.9-11.4months) vs.
14.1 months (95% CI: 12-16.3months) (p=0.0073) in the unmatched cohort.After propensity score matching, the average survival time of anemic and non-anemic patients was 10.9 months (95% CI: 8.8-12.9.months) vs. 17.8 months (95% CI: 16.0-23.3months) (p <0.001).Conclusion: Pretreatment anemia was an independent risk and prognostic factor for survival in patients with advanced NSCLC.Large-scale studies are required to confirm our findings.
Open the resolved locator · 10.7150/jca.55159
Metadata licence: OpenAlex metadata (CC0)